Menu
MapConnectionsTopicsBulgariaThe Night (K-TRIO)Marie Skłodowska-CurieFor studentsFor teachersMethodologySurprise me
HEIndividual fellowship2022–2024

SELECTFLOW · Selective Alkylation of Complex Molecules in Flow

Horizon Europe — Marie Skłodowska-Curie Actions

Duration
2022-09-01 → 2024-08-31
EU contribution
€187,624
Participants
1
Scheme
HORIZON-TMA-MSCA-PF-EF

Lines connect the coordinator with its partners.

Results in brief

Selective Alkylation of Complex Molecules in Flow

Now more than ever, there is a pressing need for sustainable and efficient chemical processes. The pharmaceutical industry faces challenges in developing greener and more efficient methods for synthesizing biologically active molecules. Gaseous chemicals, which contribute significantly to environmental pollution, present both a challenge and an opportunity for innovative solutions. Traditional chemical processes often rely on non-renewable resources and produce substantial waste, highlighting the urgent need for innovation in green chemistry. SELECTFLOW overall objectives are: 1) Development of selective, sustainable and predictable synthetic methodologies for the modification of drug-like small molecules. 2) Valorisation of gaseous chemicals, and convert them into higher added-value compounds, thus providing a sustainable solution for environmental pollution and contributing towards a circular economy. 3) Promote environmentally-friendly chemical processes that minimize waste and resource consumption, in line with the European Commission MSCA Green Charter and Horizon Europe missions: the adaptation to climate change to become climate resilient by 2030. To succeed in these objectives, SELECTFLOW presents a multidisciplinary project that lies in the intersection of synthetic photoredox catalysis with microfluidic technologies, with the objective of delivering a selective, sustainable and predictable methodology for the modification of biologically-active molecules using gaseous reagents as raw materials. The combination of multiphasic flow chemistry with the design of photocatalytic synthetic methodologies will open new and more efficient routes for the production of fine chemicals. The use of standardized continuous-flow reactors will enable researchers from various fields to carry out transformations in a reproducible and scalable fashion and will streamline the transition from academia to industrial applications.

Data: CORDIS, © European Union

Project objective

Developing new pharmaceutically-active molecules for the treatment of diseases that compromise the health and well-being of society is an essential but tedious process with rising costs, partially due to the arduous chemical synthesis of complex drug candidates. Recently, innovations in organic chemistry have streamlined the access to vast libraries of drugs by applying novel methodologies such as Late-Stage Functionalization of C-H bonds. However, one of the major challenges of editing biologically-active chemical structures is the development of processes that are compatible with diverse functional groups and functionalize one single position ""à la carte"" in an efficient and predictable manner.SELECTFLOW presents a multidisciplinary project that lies in the intersection of synthetic photoredox catalysis with microfluidic technologies, with the objective of delivering a selective, sustainable and predictable methodology for the modification of biologically-active molecules using light alkanes as raw materials. This will require the accomplishment of three specific objectives: 1) Development of a chemo- and regioselective synthetic methodology for the edition of nitrogen-containing aromatic heterocycles. 2) Translation of the developed photocatalytic system into a microflow-based setup, to enable the use of gaseous reagents in a milder and scalable fashion. 3) Understanding the mechanistic intricacies of the developed methodology in order to predict unexplored similar transformations. Overall, this proposal directly tackles one of the most important challenges for the pharmaceutical industry, the rapid and cost-effective production of innovative drugs, by delivering a sustainable valorisation of greenhouse gases, such as methane. It is expected that this innovative approach will be of high scientific, technological and societal impact, ultimately reinforcing the already European competitiveness in the production of life-saving drugs.""

Original text from CORDIS.

Participants

  • UNIVERSITEIT VAN AMSTERDAM · AmsterdamCoordinatorNetherlands

Links

Data: CORDIS, © European Union